Cargando…
The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia
Background: Chronic Myeloid Leukemia’s (CML) treatment was optimized since the development of tyrosine kinase inhibitors (TKI) and an increased overall survival during TKI was noticed. During the TKI era, protocols for assessing response and resistance to treatment were developed. Additional chromos...
Autores principales: | Crisan, AM, Coriu, D, Arion, C, Colita, A, Jardan, C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656961/ https://www.ncbi.nlm.nih.gov/pubmed/26664479 |
Ejemplares similares
-
Importance of assessing cytogenetic and molecular risk factors in acute myeloid leukemia therapy
por: Coles, EC, et al.
Publicado: (2012) -
The simultaneous occurrence of multiple myeloma and JAK2 positive myeloproliferative neoplasms - Report on two cases
por: Badelita, S, et al.
Publicado: (2015) -
High incidence of minor and micro breakpoints in Chronic Myeloid Leukaemia with additional cytogenetic abnormalities at diagnosis – the Western Australian series
por: Leung, Emily, et al.
Publicado: (2022) -
Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
por: Rychter, Anna, et al.
Publicado: (2017) -
Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia
por: Lindström, H. Jonathan G., et al.
Publicado: (2019)